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Abstract:
	
  
The purpose of my research project has been to determine the nature of the
binding relationship between caveolin and hFSHR inside sex cells. FSH plays a role in
the maturation of these cells, and interfering with the receptor’s interaction with caveolin
would prevent cell maturation (down regulating fertility). It is believed the interaction
occurs through transmembrane domain IV of the receptor due to its aromatic nature. The
treatment of sex cells with synthetic peptides that mimic the hFSHR-caveolin binding
sequence should prevent the interaction, shutting down the signaling cascade from
hFSHR. This can be tested for by the monitoring of downstream signals given off by
hFSHR, including the presence (or absence) of phosphorylated p44, PKA, and CREB. It
is hypothesized the wildtype peptide treatment will down regulate all of these signals
when compared to the mutant control. Current data points towards this hypothesis
holding true, with successful western blots displaying a noted difference in cell signaling
between the wildtype and mutant peptide treatments. These results indicate the key
interaction between caveolin and hFSHR likely occurs at transmembrane domain IV.
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Introduction:
	
  
	
  
Follicle stimulating hormone (FSH) plays an important role in the maturation of
sex cells in both males and females. FSH is part of the hypothalamic-pituitary-gonadal
axis in both males and females [1]. Upon proper stimulation, the hypothalamus sends a
signal to the anterior pituitary gland to release FSH. Its receptor, Human Follicle
Stimulating Hormone Receptor (hFSHR), is only expressed in sex cells. In females,
hFSHR is located in granulosa cells, found in the ovaries. A proper interaction between
the hormone and its receptor in ovarian cells produces estrogen, allowing proper oocyte
development. In males, the receptor is located in sertoli cells in the testis; a proper
interaction promotes spermatogenesis [2].
hFSHR is a G-Protein Couple Receptor (GPCR). It requires activation by an
agonist to pass an extracellular signal to the intracellular proteins targeted. Upon binding
an appropriate agonist, a GPCR’s alpha subunit exchanges a GDP for a GTP, becoming
active. It then frees up both beta and gamma subunits, allowing those to pass on signals
as well. A successful signal transduction cascade requires this activation mechanism to
work perfectly, with all members in the right place at the right time.
hFSHR is not readily found on the surface of these cells. It is located in the
cytosol, and requires the assistance of caveolin to be brought to the cellular membrane.
This is accomplished through a caveolin binding motif in transmembrane domain IV in
the receptor. Caveolin, a protein found in the caveolae of the cell membrane, has been
proven to transport receptors to the cell surface before. Caveolae are a set of lipid rafts
with a structure that allows them to bind and transport many cell receptors. The binding
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of hFSHR is believed to be accomplished by an interaction of transmembrane domain IV
of hFSHR with the caveolin protein [3].
Any interference with this caveolin-hFSHR interaction would effectively silence
the normally observed effects of FSH in sex cell maturation. Inversely, any up regulation
of this interaction would allow for increased maturation ability in sex cells that struggle
to mature by themselves. It is apparent this interaction can be affected either in the hopes
of silencing sex cell maturation (down regulating fertilitiy), or over expressing this
interaction (up regulating fertility).
A successful hFSHR signal cascade manifests itself in the appearance of
downstream signal transduction, most notably due to the activation of adenylyl cyclase,
producing Cyclic AMP that is bound by Protein Kinas A to activate the protein, which in
turn activates a multitude of downstream enzymes. Two of the most important
downstream signaling enzymes of this cascade are p44 Map Kinase and Cyclic-AMP
response element binding protein (CREB), as seen in Figure 1. Both of these are
phosporylated (activated) when there is a successful interaction of hFSHR with caveolin,
allowing the receptor to come to the cell surface and bind its substrate, FSH. Therefore,
monitoring the presence of activated p44 and activated CREB is an extremely effective
method of determining if there has been a disruption event in the caveolin-hFSHR
binding interaction.
It has been shown in previous
research projects that this
critical binding motif can be
blocked by the introduction of
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Figure 1. Current model for hFSHR signaling.

synthetic peptides with the same aromatic caveolin-binding motif as hFSHR. This was
noted through monitoring the amount of phosphorylated CREB in cells after treatment
with two different synthetic peptide memetics. A decrease in the amount of
phosphorylated CREB was observed after treatment with the wildtype binding memetic
when compared to the control, a mutant peptide with non-aromatic residues in the
binding motif range. There was, however, no testing for the effects of these peptides on
the amount of phosphorylated p44. This may in fact be a better indicator of the caveloinhFSHR interaction interference, as fewer upstream molecules can activate p44 compared
to CREB. In other words, CREB can be activated by a multitude of mechanisms, so any
drop in its activation could be a result of peptide interference with other activators of
CREB.
In order to allow the peptides to enter the cells, they are attached to a truncated
version of the Tat protein found in HIV. This protein allows the virus to pass through cell
membranes; it is used here to get the peptides through experimental cell membranes. The
truncated Tat used also does not change peptide folding due to its incredibly charged
nature; it truly is just a vector used to allow peptide entrance [4].
The sequences of these peptides are shown in Figure 2. The important residues
are the aromatic amino acids in red. In the wild type peptide, the red residues include the
same aromatic residues as those found in the aforementioned transmembrane domain;
these are changed to non-aromatic residues in the mutant peptide (as shown by those
residues put in bold print).

Figure	
  2	
  Custom	
  Peptides	
  used	
  in	
  previous	
  research.	
  	
  Their	
  
sequences	
  in	
  italics	
  are	
  from	
  the	
  tat	
  peptide.	
  	
  The	
  
remainder	
  of	
  the	
  sequence	
  is	
  from	
  hFSHR	
  amino	
  acids	
  479-‐
489.	
  
	
  Mutated	
  
residues	
  
are	
  shown	
  
in	
  bold. motif (Red)
Tat
(Blue)-WT
Caveolin
binding

YGRKKRRQRRRFAFAAALFPIF
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YGRKKRRQRRRLALAAALLPIL
Tat (Blue)-Mutant Caveolin binding motif

The wildtype peptide should be able to bind easily to the caveolin in the cell and
shutdown the signal cascade. If this occurs, hFSHR would be unable to to bind to its
substrate, as it would not be at the surface of the cell. This would result in a decrease in
the activation of CREB and of p44. The mutant peptide, on the other hand, won’t be able
to bind to caveolin in the cell and should not affect the amount of signaling caused by
hFSHR.
The primary antibody used in my experiment is Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) Antibody #9101, with a secondary antibody Goat anti-Rabbit IgG
(H+L) Secondary Antibody, HRP conjugate #65-6120. The advantage of using Phosphop44/42 MAPK antibody 9101 is its specificity for phosphorylated p44 MAP Kinase. It
does not cross react with phosphorylated residues of either JNK/SAPK or p38 MAP
Kinase, and does not cross-react with non-phosphorylated Erk1/2. This allows for better
results in the experiment.
My hypothesis is the cell samples treated with the wildtype peptide should show
marked differences in signaling compared to those treated with the mutant peptide.
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Methods:
A method developed by Roh et. Al [5] was adapted for use in this experiment.
Cell Culture
HEK 293R cells were used in this experiment due to their stable expression of the
desired receptor. Cells were grown in the Union College tissue culture room in sterile
conditions and split at 90% confluence to prepare them for the peptide treatments.

Peptide Treatments
Previously prepared stock solution of both wildtype and mutant peptides were
used at concentrations of 10-mM. Three 15mL conical tubes had 10 µL of WT, mutant,
or no peptide added to 10mL of serum free medium. Then, two milliliters of each mixture
was added to the appropriate well in two different 6-well dishes. The layout of these
treatments is outlined in Figure 4. Peptide treatments lasted an hour for the cells, allowing
them to affect the HEK293R cells in the wells.

Treatment with FSH
4.8 µL of hFSH was mixed into 1.2mL of SFM to create the stock treatment
solution while the peptide incubation was occurring. Once the peptide treatment was
over, the media in the 6-well dishes was sucked off and replaced with 4mL of fresh SFM
to ensure no peptide residue remained. 100µL of the prepared hFSH stock solution was
added to the appropriate wells in the dishes as outlined in Figure 5. Incubation took place
for periods of 30, 15, 5 and zero minutes to see how signaling changes over time with the
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treatments. Once the desired time had elapsed, the media was aspirated off the cells to
remove any lingering hFSH.

Cellular Extractions
Immediately following media aspiration, the dishes were placed on ice and each
well underwent two washes with 1mL of freezing PBS. In order to lyse open the cells, a
solution of lysis buffer was created. One phosSTOP tablet and one cOmplete tablet were
added to 10mL of lysis buffer and 500µL of this mixture was added to each well and
incubated for 20 minutes. The phoSTOP tablet prevents depshosphorylation of
phosphorylated proteins (the data to be examined) and the cOmplete tablet prevented
those proteins from being cleaved by proteases (4,5). The well contents were then
scraped into twelve microfuge tubes on ice (contents detailed in Table 1). The contents of
each tube were transferred into a dounce homegnizer, dounced to ensure all cells had
been lysed open, then returned to their microfuge tube. After all cells had been dounced,
the tubes were centrifuged at maximum speed for ten minutes with the supernatants
collected and placed into different microfuge tubes (Table 2).

BCA Assay
To determine the concentrations of protein in each cell sample, a bicinchoninic
acid protein assay was performed. 10 µL of eight standards of pre-determined
concentrations were loaded in triplicate on the appropriate 96 well-microplate. The
unknown samples were also added in incriments of 10µL in triplicate to the
corresponding wells on the plate reader. Once all standards and samples had been loaded,
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a working reagent was prepared from the BCA kit at 50:1 ratio of A to B. 200µL of this
reagent was pippeted into each well to help with protein determination. A plastic cover
was placed on top of the microplate, and it was placed in an incubator at 37C for a half
hour. After this incubation period, the plate was loaded into the appropriate assay reader
and a standard curve was created. The samples were compared to the curve by the assay
to determine their average protein content (from the standard curve). This information
was printed out and used to standardize all samples to the lowest concentration sample,
diluting the extremely concentrated samples. This allowed for the creation of evenly
concentrated samples, as not to incorrectly read a signal as having a stronger reaction to
FSH when it was due to the higher level of protein in the sample. Gel samples had a total
volume of 200µL, with up to 100µL of sample and the remainder filled in by 2X SDS
buffer. These samples were boiled at 70C for 30 minutes once prepped and then frozen
for later usage.

Gel Electrophoresis
3.5 mL of 10% SDS-polyacrlyamide resolving gel was added to each gel
apparatus, covered in isopropyl alcohol and allowed to sit for an hour to set. Once the
hour was up, the isopropyl was poured out, and a 4% SDS-polyacrylamide stacking gel
was used to fill the rest of the apparatus with a 10 well comb placed in the gel and
allowed to set for 30 minutes. The comb was removed once the gel was set to create the
loading wells for the samples. 20µL of a protein molecular weight marker was added in
the first well of each gel ran, with the aforementioned prepared gel samples added (20
µL) to the appropriate wells to analyze the amount of signaling the specific well had

	
   9	
  

undergone. The gels were then run at 60-65 minutes at 100 volts for one hour in prepared
1X electrophoresis buffer.

Western Blotting
In order to visualize the results of the gel electrophoresis step, a western blot was
performed. Gels were removed from the glass plates and soaked in transfer buffer for
fifteen minutes. In order to transfer the gels, six separate Watmen filter papers were cut
for each gel at 3.25X2 inch measurements, with one nitrocellulose membrane for each gel
also cut to that size. The membranes were dipped in methanol and soaked in transfer
buffer for 10 minutes. Once the gels and membranes had been soaked for the appropriate
amounts of time, “sandwiches” were made: 3 of the Watman filter papers dipped briefly
in transfer buffer, the membrane, the gel, and 3 more Watman filter papers on top. This
set-up was then run on a semi-wet transfer cell apparatus for 15 minutes at 15 volts to
pass the proteins from the gel to the membrane. Once the transfer was complete, the
membranes were soaked in 5% milk in 1XTBST for 60 minutes for blocking in a sealed
bag.
While blocking occurred, solutions of primary antibodies were prepared. The
antibodies used were” P-p44 to detect phosphorylated p44 MAPK, P-CREB to detect
phosphorylated CREB and P-PKA to detect phosphorylated PKA proteins. The standard
concentration was 5µL of antibody to 10mL of 5%BSA in 1XTBST. At the end of the
blocking period, the membranes were placed in new bags with the appropriate primary
antibody and left to soak in them overnight in the Wold cold room. The next day,
solutions of secondary antibody were prepped with the standard concentration being 5µL
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of antibody to 10mL of 5% milk. The membranes were then removed from their primary
antibody bags, washed 3 times for 5 minutes in 1XTBST before being placed in new bags
with the appropriate secondary antibody for another hour long incubation. At the end of
this incubation, the membranes were removed from the bags, washed in 1X TBST for 3
sets of 5 minutes each, then soaked in Thermo Scientific SuperSignal® West Pico
Chemiluminescent Substrate for 5 minutes to develop an image of the transferred
proteins. The membranes were then photographed with the BioRad ImageLab and
analyzed for protein expression.
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Results:

Figure 3. Western Blot of peptide and hormone treatments. Antibody used was for proteins
phosphorylated by Protein Kinase A. CIM peptide is the wildtype peptide, non-cim is the mutant peptide.

The western blot shown in Figure 3 shows a clear difference in signaling between
cell samples treated with the wildtype peptide, and those treated with the mutant peptide.
There is very little downstream phosphorylation of proteins by PKA in the wildtype
peptide until the 15 minute mark. This strong signal falls off at the 30 minute mark. The
mutant peptide reaches a maximum signal at the 5 minute mark, 10 minutes faster than
the wildtype peptide. This signal proceeds to tail off both the 15 and 30 minute mark. The
maximum signal for the mutant peptide (5 minute mark) is larger than the maximum
signal for the wildtype peptide treatment (15 minute mark). There is a clear difference in
the signaling patterns, both in timing and intensity, as anticipated in the hypothesis.
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Figure 4. Western Blot for peptide and hormone treatments. Antibody used was anti-phospho-p44

The western blot in figure 4 shows a difference in timing and level of activation
of P44 between the mutant and wildtype peptides. The wildtype peptide treatments show
almost no signaling for the first 3 time points. It only begins to appear at the 30-minute
mark, with the maximum occurring after a half hour of FSH stimulation. The mutant
peptide treatments show a maximum occurring at the 15-minute time point, continuing
over into the 30 minute time point, There is almost no signal for the mutant peptide for
the first two time points. Again, there is clearly a difference between the level and timing
of activation of P44 in cell samples treated with either the wildtype or mutant peptides.
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Discussion:
The results from this experiment support my hypothesis. Beginning with a
detailed observation of Figure 3, there is a clear difference in signaling between the
wildtype peptide treated cell samples and those treated with the mutant peptide. Again,
the wildtype peptide shares the theorized aromatic amino acid residues believed to exist
in the caveolin-hFSHR motif (transmembrane domain IV). The interruption of
downstream signaling from PKA shows there has been interference with the hFSHR in
these cells. This is likely, although not certainly, due to a binding interaction occurring
between caveolin and the wildtype peptides that have entered the cell. This binding
prevents the downstream signaling from taking place in the cells. The mutant peptide
treatment serves as the control for the monitoring of proteins phosphorylated by PKA, so
any difference noted between wildtype and mutant supports the hypothesis. There is a
clear difference; therefore the wildtype peptide must have interfered with the signaling,
most likely by binding to caveolin and preventing the receptor from reaching the surface.
The results in Figure 4 also support the hypothesis of the experiment. There is a
clear difference in the timing and level of activation of P44 in the cells treated with either
wildtype or mutant peptide. This is again likely caused by an interference with caveolinhFSHR localization when cells are treated with the wildtype peptide that is able to bind
with the caveolin.
While my results are limited in scope, similar experiments with similar outcomes
have been performed before. The possibility that the wildtype peptide is able to interfere
with the direct interaction of caveolin with the GPCR is supported in a study done by
Kim et Al [6]. They examined the interaction of the mGlu-1 receptor (a GPCR) with
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caveolin through the use of both “blocking” and “mutant” peptides. The blocking peptide
had the aromatic amino acid residues theorized to mediate the binding between caveolin
and the receptor, while the mutant peptide had non-aromatic amino acids at those
residues. Upon separate co-immunoprecipitation experiments of both caveolin and mGlu
receptor, it was clear they did not associate in cells treated with the blocking peptide. The
peptide treatment was preventing the binding of the receptor to caveolin when it
contained the aromatic amino acid residues, similar to my experiment. Further
experimentation showed this interference with the binding interaction between caveolin
and the receptor prevented its localization to lipid rafts. This was accomplished through
peptide treatments and double-labeling immunocytochemistry of endogenous mGlu1α
receptor and lipid rafts. There were again significant differences in the localization of the
receptor in lipid rafts between blocking and non-blocking peptides. All of these data
together support a receptor-caveolin interaction being key for the receptor to become
localized in lipid rafts. mGlu-1 receptor is a GPCR, like hFSHR, and this similarity
shows a related mechanism is likely occurring in my experiment.
Experimental data produced by Bhatanger, et Al., also supports a proposed
interaction between caveolin and GPCRs [7]. Instead of using peptide treatments to
interfere with the theorized interaction between GPCRs and caveolin, the researchers
used siRNA to knockdown the expression of caveolin in a variety of cell lines, most
notably C6 glioma cells, that expressed both 5-HT(2A) and Galpha(q)-coupled P2Y
purinergic receptor. Prior to the knockdowns, co-immunoprecipitation studies showed the
caveolin was associating with the receptors in control cell lines. This of course shows
there is an interaction between caveolin and the GPCRs in the cells and is an experiment
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that should be performed on hFSHR in the future. Knockouts took place after this first
experiment proved the interaction existed. The cells with knocked out caveolin showed
decreased cell signaling from both GPCRs when compared to control cell lines with
normal levels of caveolin expressed in them. This data was gathered by measuring cell
signaling with calcium flux assays in the cells after knockdowns occurred. The results of
this experiment further support the conclusion that there is likely an interaction between
GPCRs and caveolin that is critical to the function of the receptors. The cells were unable
to pass on signals from those receptors after caveolin was eliminated from the cells,
showing caveolin to be related to their function. Although this experiment did not
investigate where that interaction was taking place on the receptor, its data still supports
the results from my peptide treatment experiments.
The evidence in the literature and in my experiment points to supporting a
caveolin-GPCR binding interaction to localize to lipid rafts in cell membranes. In the
case of hFSHR, this is important for a multitude of reasons mentioned before. The
primary field affected by a proper study of the hFSHR-caveolin interaction is fertility [5].
The ability of a drug to interfere with the hFSHR-caveolin interaction motif would
revolutionize contraception treatments. Current drugs that serve as birth control are
commonly taken in pill form and involve the use of synthetic estrogen and progestin [8].
They aren’t quite 100% effective, especially when the drug regimen isn’t followed
strictly. Hormone imbalances can occur, and improvements can definitely be made in the
design of these drugs.
This is exactly where a drug that is able to interfere with the hFSHR-caveolin
interaction would be a lifesaver. It wouldn’t require synthetic hormone treatments; it
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would theoretically simply prevent the maturation of sex cells in both men and women. A
birth control treatment for both sexes would revolutionize how we view contraception,
with reproductive responsibility not just falling on the shoulders of women if this
treatment came to fruition. Given that spermatogenesis and follicular development both
require a successful signaling cascade from hFSH, preventing the receptor from reaching
the surface would allow the body to produce normal levels of FSH without any sex cell
maturation. This type of silver bullet treatment is still far down the road, but there is
promise in interfering with hFSHR-caveolin interactions. The data gathered in this
experiment and in the literature shows a decrease in GPCR downstream signaling when
cell samples are treated with peptides designed to block the aforementioned interaction.
However, there are issues with duration of treatment in the experiment. Even the
wildtype peptide inhibitor lost its effect between 15 and 30 minutes and normal signaling
returned. This could be due to the production of new receptors or new caveolin, or a
binding affinity issue with the peptide to the caveolin (i.e. it isn’t that strong and
eventually dissociates). There needs to be more data gathered on the ability of a drug to
block out caveolin-hFSHR binding in sex cells, but this potential drug target would be
fantastic. It would eliminate the requirement for synthetic hormone treatments and keep
the same efficacy as current drug treatments if not improve upon it.
The idea of creating a drug treatment for birth control that would simply prevent
hFSHR from being brought to the surface is sound in logic but still far down the road
from being realized. There needs to be a multitude of other studies performed to confirm
the localization of hFSHR in lipid rafts is a direct result of its interaction with caveolin. If
there were a different mechanism used by the cell to bring the receptor to the lipid rafts at
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the surface that is also blocked by the peptide, then the data above are false positives. The
first study needs to of course first be replication of the western blots to confirm
downstream signaling is affected by the peptide treatments and it was not experimental
error. The next step after this would be co-immunoprecipitating caveolin in both peptide
treatments and seeing if the peptide is binding to it, or if the receptor is still able to bind
to the caveolin. If the wildtype peptide were found to be binding to caveolin, it would
confirm that the aromatic amino acid residues at transmembrane domain IV of the
hFSHR are almost certainly binding to caveolin to be transported to lipid rafts in the cell
surface. This would prove the binding motif is critical for hFSHR function, and open a
new door for a potentially longer lasting drug treatment in blocking the receptor from
being brought to the surface of the cell.
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